Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yongting, Feng, Bing, Abudoureyimu, Mubalake, Zhi, Yingru, Zhou, Hao, Wang, Ting, Chu, Xiaoyuan, Chen, Ping, Wang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848262/
https://www.ncbi.nlm.nih.gov/pubmed/31750247
http://dx.doi.org/10.3389/fonc.2019.01156
Descripción
Sumario:As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sorafenib resistance have not been extensively characterized yet. Herein, we summarize the mechanisms of recently reported ncRNAs involved in sorafenib resistance and discuss the potential strategies for their application in the battle against HCC.

Ejemplares similares